CDC Vaccine Guidance Stalls Amid Political and Legal Turmoil
The CDC has not recommended a newly FDA-approved flu vaccine, illustrating a broader halt in federal vaccine guidance. The article attributes the disruption to vaccine-skeptical officials in the Trump administration and to legal challenges that followed changes to the Advisory Committee on Immunization Practices. Public deliberation and decisions on vaccine policy questions have diminished as a result.
The FDA cleared a new flu shot, mRNA-1010 (mFlusiva), after favorable results in older adults, yet the CDC has issued no guidance on its use. This gap reflects a broader breakdown: for six decades, ACIP publicly weighed vaccine evidence and sent recommendations to the agency’s leader, shaping insurance coverage.
After the committee was dismissed and replaced with skeptics, a lawsuit by pediatric and medical organizations led a federal judge to halt meetings and suspend a reduction in childhood vaccine recommendations. Physician groups now confer privately with a Minnesota researcher and publish their own guidance, which private insurers have followed.
The stalled guidance may leave clinicians and patients without a single authoritative source on newer vaccines, potentially widening disparities if recommendations vary by professional society or insurer. Older adults and children could be especially affected, since coverage and access often follow official recommendations. The shift may also erode public confidence in federal health agencies, though independent expert guidance could preserve some protections.